1What is the most common cause of abdominal pain in children?
Constipation
2How long must difficulty or delay in defecation persist to meet the lecture's definition of constipation?
At least 2 weeks with significant distress
3What percentage of pediatric office visits are due to constipation?
3–5%
4What is the incidence of constipation among children aged 6–12 years?
More than 30%
5Which sex is more commonly affected by constipation?
Males
6What are the three broad etiologic categories of constipation?
Anatomic, functional, and medical
7What is the worldwide prevalence of functional constipation?
Approximately 9.5%
8What percentage of constipation cases in children older than 1 year are functional?
More than 95%
9What is the most common age-related pattern of bowel movements in infants?
More frequent than older children and adults
10How often should an adequately toilet-trained child older than 3 years ideally defecate?
At least once daily
11What interval between bowel movements may be abnormal in adults?
More than 3 days
12What is the mean daily bowel movement frequency in breastfed infants aged 0–3 months?
2.9 times
13What is the mean daily bowel movement frequency in formula-fed infants aged 0–3 months?
2.0 times
14What is the mean daily bowel movement frequency in infants aged 6–12 months?
1.8 times
15What is the mean daily bowel movement frequency in children aged 1–3 years?
1.4 times
16What is the mean daily bowel movement frequency in children older than 3 years?
1.0 time
17What stool consistency scale is used to assess constipation?
Bristol Stool Form Scale
18What stool appearance is commonly associated with functional constipation?
Large-diameter stools
19What type of stool may suggest anatomic obstruction?
Ribbon-like stools
20What is stool withholding?
Voluntary retention of stool to avoid painful defecation
21What are common associated symptoms of constipation?
Pain, straining, hard stools, blood, withholding, soiling, and incomplete evacuation
22What is the typical presentation of functional constipation?
Infrequent, hard, or painful stools with withholding or fecal incontinence
23What is functional constipation considered diagnostically?
Diagnosis of exclusion
24What underlying causes are absent in functional constipation?
Structural, neurologic, or systemic causes
25What is the primary mechanism of functional constipation?
Painful defecation leading to voluntary stool withholding
26What initiates the withholding-pain cycle?
Painful or frightening passage of a large, hard stool
27What happens when a child voluntarily withholds stool?
Stool remains longer in the colon
28What happens to stool during prolonged retention?
More water is absorbed, making stool harder and larger
29What happens to the rectum during chronic stool retention?
Rectal distension and reduced sensation
30What causes overflow fecal incontinence?
Retained stool with leakage around impacted feces
31What reinforces the withholding-pain cycle?
Pain, fear, and avoidance
32What social consequence can overflow soiling cause?
Foul odor and peer rejection
33What is the typical withholding posture shown in the lecture?
Leg crossing or squatting
34What is retentive posturing?
Posture adopted to avoid defecation
35What is the Rome IV criterion for functional constipation in infants and children up to 4 years?
At least 2 criteria for at least 1 month
36What is the Rome IV defecation-frequency criterion in children up to 4 years?
Two or fewer defecations per week
37What is another Rome IV criterion in children up to 4 years?
History of excessive stool retention
38What stool characteristic is included in Rome IV criteria for children up to 4 years?
Painful or hard bowel movements
39What stool size is included in Rome IV criteria for children up to 4 years?
Large-diameter stools
40What rectal finding is included in Rome IV criteria for children up to 4 years?
Large fecal mass in the rectum
41What is the Rome IV criterion duration for children with developmental age of at least 4 years?
At least 1 month
42How many criteria are required for Rome IV diagnosis in children aged at least 4 years?
At least 2 criteria
43What is the frequency criterion for children aged at least 4 years?
Two or fewer toilet defecations per week
44How frequent must fecal incontinence occur to meet a Rome IV criterion in children aged at least 4 years?
At least 1 episode per week
45What behavioral finding qualifies as a Rome IV criterion in older children?
Retentive posturing or excessive stool retention
46What abdominal finding qualifies as a Rome IV criterion in older children?
Large fecal mass in the rectum
47What type of stools may obstruct the toilet in older children with constipation?
Large-diameter stools
48What is an important neonatal history question when evaluating constipation?
When meconium was first passed
49When should meconium normally be passed according to the lecture?
Within 24–48 hours after birth
50What delayed meconium passage suggests an organic cause?
After 48 hours
51What age of onset is an alarm feature for constipation?
During the first month of life
52What stool shape is an alarm feature for constipation?
Ribbon-like or narrow stools
53What type of rectal bleeding is an alarm feature?
Persistent blood in stools without an anal fissure
54What type of vomiting is an alarm feature for constipation?
Bilious vomiting
55What abdominal finding is an alarm feature?
Severe abdominal distension
56What systemic symptoms are alarm features?
Fever or unexplained diarrhea
57What growth finding suggests an organic cause of constipation?
Poor weight gain or failure to thrive
58What family history is an alarm feature?
Hirschsprung disease or relevant genetic disorders
59What does an abnormal anal position suggest?
Anorectal malformation
60What neurologic findings are examination red flags?
Abnormal lower-limb tone or reflexes and absent anal wink
61What sacral findings suggest spinal dysraphism?
Tuft of hair, deep sacral dimple, or gluteal cleft deviation
62What growth findings are examination red flags?
Abnormal growth parameters
63What are common infant causes of constipation?
Hirschsprung disease, anorectal malformations, neurologic disorders, and metabolic causes
64What congenital neurologic conditions can cause constipation?
Myelomeningocele, spina bifida, and tethered cord
65What metabolic conditions can cause constipation?
Hypothyroidism, hypercalcemia, hypokalemia, and diabetes insipidus
66What genetic disease may cause constipation in children?
Cystic fibrosis
67What gastrointestinal disease may cause constipation in older children?
Celiac disease
68What medications may cause constipation?
Opioids, anticholinergics, iron, and some anticonvulsants
69What is the primary pathologic abnormality in Hirschsprung disease?
Absence of ganglion cells in the myenteric plexus
70What happens to the affected intestinal segment in Hirschsprung disease?
Persistent contraction
71What happens to the normal proximal segment in Hirschsprung disease?
Dilatation due to stool accumulation
72What condition results from proximal intestinal dilatation in Hirschsprung disease?
Megacolon
73What is the characteristic onset of Hirschsprung disease?
Since birth or within 1–2 months of age
74When does functional constipation commonly begin?
After 1 year of age
75Is fecal soiling common in Hirschsprung disease?
No; feces do not pass normally
76Is fecal soiling common in functional constipation?
Yes
77Is straining during defecation typical of Hirschsprung disease?
No
78Is straining during defecation typical of functional constipation?
Yes
79Can patients with Hirschsprung disease commonly pass large, bulky stools?
No; ribbon-like stools may occur
80Can patients with functional constipation pass large, bulky stools?
Yes
81Are pain and bleeding during defecation typical of Hirschsprung disease?
Unusual
82Why can pain and bleeding occur in functional constipation?
Mucosal tears
83Are anal fissures usually present in Hirschsprung disease?
No
84Are anal fissures common in functional constipation?
Yes
85What is the typical rectal examination finding in Hirschsprung disease?
Empty rectum with explosive stool release after finger withdrawal
86What is the typical rectal examination finding in functional constipation?
Rectum full of hard stool
87What does a barium enema show in Hirschsprung disease?
Transition zone between narrowed distal and dilated proximal bowel
88What is the beaking sign?
Characteristic beak-like appearance on barium enema
89What is the diagnostic finding on rectal biopsy in Hirschsprung disease?
Absent ganglion cells
90What is the rectal biopsy finding in functional constipation?
Ganglion cells are present
91Which investigation definitively confirms Hirschsprung disease?
Rectal biopsy
92What is the 2026 joint ESPGHAN/NASPGHAN treatment guideline's significance?
First updated treatment guideline since 2014
93How many randomized trials were reviewed in the 2026 joint guideline?
102
94How many recommendations were included in the 2026 guideline?
11 recommendations and 19 good-practice statements
95Which constipation intervention received the only strong recommendation in the 2026 guideline?
Polyethylene glycol (PEG)
96What is the 2025 NASPGHAN position paper about?
Pediatric refractory constipation
97What does the 2026 NASPGHAN–AGA clinical care pathway emphasize?
Early recognition, stepwise care, and continuity
98What are the main components of constipation diagnosis?
Rome IV criteria, focused history, and physical examination
99What should be assessed during physical examination of a constipated child?
Growth, abdominal findings, perianal anatomy, sacral region, and neurologic status
100What is assessed during abdominal palpation?
Fecal mass or abdominal distension
101What is important when inspecting the perianal region?
Anal position and sacral anatomy
102When should digital rectal examination be performed?
Only when indicated and appropriate
103Is routine laboratory testing indicated in typical functional constipation?
No
104Is routine abdominal radiography indicated for diagnosing constipation?
No
105When should laboratory investigations be considered?
When red flags, atypical presentation, or refractory disease are present
106Which laboratory tests may be considered for suspected organic constipation?
Celiac serology, TSH, and calcium
107What are the three mainstays of initial functional constipation management?
Increase fluid and fiber intake and establish a regular bowel routine
108What percentage of functional constipation cases improve with appropriate management?
90–95%
109When is abdominal radiography appropriate in constipation?
When history or examination is unreliable or obstruction/distension is suspected
110What test is used to evaluate RAIR and anorectal function?
Anorectal manometry
111When is contrast enema indicated?
When Hirschsprung disease or an anatomic abnormality is suspected
112What is the role of rectal biopsy in constipation evaluation?
Confirmation of Hirschsprung disease
113What are the goals of constipation treatment?
Soft painless stools, clearing fecal loading, preventing recurrence, and restoring confidence
114What should clinicians avoid when counseling families about constipation?
Blame, punishment, and shame
115What is the first step before maintenance therapy?
Assess and treat fecal impaction
116What clinical findings suggest fecal impaction?
Prolonged absence of voluntary stool passage and hard, difficult stools
117Which Bristol Stool Form Scale types suggest hard stools and possible impaction?
Types 1–2
118What examination finding suggests fecal impaction?
Palpable hard fecal mass
119Can overflow fecal incontinence coexist with fecal impaction?
Yes
120What are the treatment options for fecal disimpaction?
High-dose oral PEG or rectal enema
121What is the common PEG disimpaction dose?
$1–1.5$ g/kg/day
122How long is the common PEG disimpaction regimen?
3–6 days
123What factors should guide enema selection?
Age, treatment burden, contraindications, and local protocol
124Why should acceptability of rectal therapies be discussed?
They can be distressing to children
125What is the first-line maintenance medication for pediatric functional constipation?
Polyethylene glycol (PEG 3350/4000)
126What is the typical PEG maintenance dose?
$0.4–0.8$ g/kg/day
127Can PEG be administered with or without electrolytes?
Yes
128How should PEG maintenance dosing be adjusted?
According to response and tolerance
129What stool characteristics are targeted during PEG maintenance therapy?
Soft, painless stools
130What behavioral outcomes are targeted during PEG maintenance therapy?
Minimal withholding and minimal soiling
131Why should PEG continue after disimpaction?
To prevent fecal re-accumulation
132What are common adverse effects of PEG?
Bloating, abdominal discomfort, and loose stools
133What should be explained when starting PEG?
Expected onset, mixing instructions, and adherence
134Should PEG be stopped as soon as stool frequency improves?
No; review overall treatment response
135When is lactulose useful in pediatric constipation?
When PEG is unavailable or not tolerated
136What is the evidence recommendation for magnesium hydroxide?
Conditional recommendation with low-certainty evidence
137What is the therapeutic role of senna, bisacodyl, and sodium picosulfate?
Adjunct, rescue, or selected maintenance therapy
138What is linaclotide used for in selected pediatric constipation cases?
A suggested option with conditional recommendation
139What is the evidence certainty for linaclotide?
Moderate-certainty evidence
140What should be considered before prescribing linaclotide?
Specialist guidance and local approval
141Is prucalopride suggested for pediatric functional constipation?
No; evidence shows no benefit
142Are lubiprostone and domperidone suggested for pediatric functional constipation?
No
143What is the role of toilet sitting in constipation management?
Relaxed, developmentally appropriate sitting after meals
144What is the recommended foot position during toilet sitting?
Feet supported on a stool
145How should the knees be positioned during toilet sitting?
Above the hips
146What is the recommended trunk position during toilet sitting?
Lean forward
147What behavioral approach should be used during toilet training?
Positive reinforcement
148What should be avoided during toilet training?
Punishment
149What tool helps monitor bowel habits during treatment?
Stool diary
150What dietary intake should children with constipation maintain?
Normal age-appropriate fiber and fluid intake
151Should excessive fluid or fiber intake be prescribed?
No
152What physical activity is recommended for children with constipation?
Regular physical activity
153Should behavioral therapy be used alone for constipation?
No; use it as an adjunct when indicated
154What is the evidence certainty for pelvic floor physiotherapy in selected children?
Low-certainty evidence
155What is the evidence for probiotics in pediatric constipation?
Low-certainty and strain-specific
156When may a cow's milk-free trial be considered?
When conventional therapy fails and cow's milk allergy is suspected
157How long should a cow's milk-free trial last?
2–4 weeks
158Why should restrictive diets involve a dietitian?
To ensure nutritional adequacy
159Is biofeedback alone recommended for pediatric constipation?
No
160Can biofeedback be included in broader pelvic floor physiotherapy?
Yes
161Are enemas and suppositories routine maintenance treatments?
No; they may be used in selected children
162What is the minimum recommended duration of maintenance therapy?
At least 2 months
163How long should symptoms be resolved before tapering treatment?
At least 1 month
164Should maintenance therapy be stopped abruptly when improvement begins?
No; taper gradually
165What stool parameters should be monitored during follow-up?
Frequency and consistency
166What behavioral symptoms should be monitored during follow-up?
Pain, withholding, and fecal soiling
167What treatment-related factors should be assessed during follow-up?
Adherence, dose adequacy, adverse effects, and family burden
168How long may many children require constipation treatment?
Several months
169What is the first requirement for diagnosing refractory constipation?
Meeting Rome IV criteria for functional constipation
170How long must age-appropriate therapy fail before refractory constipation is considered?
At least 3 months
171What medication is required in optimized therapy for refractory constipation?
Daily stimulant laxative
172What interventions should accompany stimulant laxatives in refractory constipation?
Behavioral and biomechanical interventions
173What persistent stool frequency supports refractory constipation?
Two or fewer voluntary defecations per week
174What persistent fecal incontinence frequency supports refractory constipation?
At least 1 episode per week
175What quality-of-life feature is required for refractory constipation?
Impaired quality of life of the child or family
176What should be excluded before diagnosing refractory constipation?
Alarm features and organic disease
177What treatment factors should be verified before labeling constipation refractory?
Adherence, dosage, duration, and medication access
178What must be addressed before optimizing maintenance treatment?
Fecal impaction
179Is failure of PEG alone sufficient to diagnose refractory constipation?
No; an adequate stimulant trial is needed
180Which specialist team may manage refractory constipation?
Pediatric GI or motility team
181Which serologic test should be obtained before invasive testing or surgery?
Celiac serology
182When should thyroid testing be considered?
When suggestive alarm features are present
183When is anorectal manometry considered?
To assess RAIR and anorectal function
184When is spinal MRI considered?
For specialist-directed investigation of suspected spinal pathology
185What is the role of multidisciplinary care in refractory constipation?
Optimize conventional treatment and coordinate specialist interventions
186What specialist interventions may be considered in refractory constipation?
Linaclotide, pelvic floor physiotherapy, and transanal irrigation
187When may botulinum toxin or surgery be considered?
Carefully selected refractory cases
188Which professionals may participate in multidisciplinary constipation care?
Pediatrics, surgery, psychology, and dietetics
189What are common constipation management pitfalls?
Under-treatment, premature discontinuation, and failure to disimpact
190Why is relying only on dietary changes often inadequate?
It may fail to treat fecal impaction and chronic retention
191Does daily stool passage exclude constipation?
No; retention and soiling may persist
192Should fecal soiling be considered intentional misbehavior?
No
193What is the likely diagnosis in a 5-year-old with painful large stools twice weekly, withholding, and weekly soiling?
Functional constipation by Rome IV
194What should be addressed first in a child with functional constipation and palpable fecal mass?
Fecal disimpaction
195What is the recommended initial management of functional constipation with impaction?
Disimpaction with oral PEG or an appropriate rectal option
196What maintenance medication follows disimpaction?
PEG
197What additional measures should accompany maintenance treatment?
Toilet routine, education, and follow-up
198What are the key take-home principles for pediatric constipation?
Diagnose clinically, identify red flags, disimpact first, and use PEG first-line
199What is the recommended duration of optimized treatment before diagnosing refractory constipation?
At least 3 months
200What is the first step in bilirubin metabolism?
Breakdown of old red blood cells
201What are the two components produced by red blood cell breakdown?
Heme and globin
202What is heme converted into first?
Biliverdin
203What is the next product after biliverdin?
Unconjugated bilirubin
204What color is biliverdin?
Greenish
205What type of bilirubin is unconjugated bilirubin?
Indirect bilirubin
206Is unconjugated bilirubin fat-soluble or water-soluble?
Fat-soluble
207Can unconjugated bilirubin be directly excreted in urine or bile?
No
208What protein transports unconjugated bilirubin in the bloodstream?
Albumin
209Which organ conjugates bilirubin?
Liver
210Which liver cells perform bilirubin conjugation?
Hepatocytes
211Which enzyme conjugates unconjugated bilirubin?
UDP-glucuronosyltransferase
212What substance is attached to unconjugated bilirubin during conjugation?
Glucuronic acid
213What type of bilirubin is produced after conjugation?
Conjugated or direct bilirubin
214Is conjugated bilirubin fat-soluble or water-soluble?
Water-soluble
215Where is conjugated bilirubin secreted?
Bile
216Where does conjugated bilirubin enter after bile secretion?
Small intestine
217What do gut bacteria convert conjugated bilirubin into?
Urobilinogen
218What substance gives stool its brown color?
Stercobilin
219What is most urobilinogen converted into?
Stercobilin
220What happens to a small portion of urobilinogen?
Reabsorbed into blood and filtered by kidneys
221What substance gives urine its yellow color?
Urobilin
222What causes unconjugated hyperbilirubinemia?
Increased bilirubin production, impaired uptake, or defective conjugation
223What enzyme defect can cause unconjugated hyperbilirubinemia?
UGT1A1 dysfunction
224What is the major mechanism of unconjugated hyperbilirubinemia?
Hemolysis, impaired hepatic uptake, or defective conjugation
225What are causes of unconjugated hyperbilirubinemia?
Physiological jaundice, breast milk jaundice, ABO/Rh isoimmunization, G6PD deficiency, and inherited syndromes
226Which inherited syndromes cause unconjugated hyperbilirubinemia?
Crigler–Najjar and Gilbert syndromes
227What causes conjugated hyperbilirubinemia?
Defective bile formation, excretion, or extrahepatic biliary obstruction
228What is another name for conjugated hyperbilirubinemia?
Cholestasis
229What are causes of conjugated hyperbilirubinemia?
Biliary atresia, Alagille syndrome, PFIC, alpha-1 antitrypsin deficiency, TORCH infections, and metabolic disorders
230What does PFIC stand for?
Progressive familial intrahepatic cholestasis
231What is the ESPGHAN/NASPGHAN two-week rule?
Evaluate infants with persistent jaundice for cholestasis
232At what age must a jaundiced infant be evaluated for cholestasis?
At least 14 days
233At what age may evaluation be extended for exclusively breastfed infants with reassuring findings?
At least 21 days
234What direct bilirubin level is considered abnormal in the lecture?
Greater than 1.0 mg/dL
235What is the equivalent abnormal direct bilirubin level in the lecture?
17 mmol/L
236Does an abnormal direct bilirubin require investigation regardless of total serum bilirubin?
Yes
237What screening tool can identify acholic stools early?
Stool color cards
238What stool color suggests cholestasis?
Acholic or pale stools
239What initial laboratory tests are included in the neonatal cholestasis workup?
Total and fractionated bilirubin, ALT, AST, GGT, alkaline phosphatase, albumin, and PT/INR
240Which infectious investigations are included in the neonatal cholestasis workup?
TORCH panel, blood and urine cultures, CMV PCR, HSV, and enteroviruses
241Which metabolic and genetic investigations are included in the neonatal cholestasis workup?
Newborn screen review, galactosemia testing, A1AT level/phenotype, and NGS panels
242What imaging is used in neonatal cholestasis evaluation?
Fasted abdominal ultrasound
243What ultrasound findings are assessed for suspected biliary atresia?
Gallbladder size, triangular cord sign, and extrahepatic bile duct anatomy
244What invasive investigations may be used for neonatal cholestasis?
Percutaneous liver biopsy or intraoperative cholangiogram
245Why is early identification of direct bilirubin important?
To detect cholestasis and enable timely referral
246Why is suspected biliary atresia urgent?
It is a surgical emergency
247What procedure treats biliary atresia?
Kasai portoenterostomy
248When should Kasai portoenterostomy ideally be performed?
Before 45–60 days of life
249What is the benefit of early Kasai portoenterostomy?
Improved native liver survival
250What is the purpose of post-Kasai antibiotic prophylaxis?
Prevention of cholangitis
251Which antibiotics may be used for post-Kasai cholangitis prophylaxis?
TMP-SMX or neomycin
252What is the role of adjuvant steroids after Kasai portoenterostomy?
Improve bile drainage according to institutional pathways
253What nutritional support is recommended after Kasai portoenterostomy?
High-calorie feeding at 130–150% of estimated average requirement
254What type of formula is recommended in cholestatic infants?
MCT-enriched formula
255Which vitamins require water-soluble supplementation in cholestasis?
Vitamins A, D, E, and K
256What is the purpose of phototherapy in neonatal unconjugated hyperbilirubinemia?
Lower serum bilirubin
257What factors determine phototherapy thresholds?
Hour-specific TSB, gestational age, and neurotoxicity risk factors
258What are neurotoxicity risk factors for neonatal hyperbilirubinemia?
Sepsis, hemolysis, acidosis, and low albumin
259What type of light is used for intensive phototherapy?
High-intensity LED
260What is the recommended intensive phototherapy irradiance in the lecture?
30 W/cm²/nm
261What should intensive phototherapy maximize?
Surface area exposed to light
262When is IVIG considered in immune hemolytic disease?
When TSB rises despite intensive phototherapy or approaches exchange level
263What is the IVIG dose for immune hemolytic disease?
$0.5–1.0$ g/kg
264When is exchange transfusion indicated?
Critical TSB levels or signs of acute bilirubin encephalopathy
265What does ABE stand for?
Acute bilirubin encephalopathy
266What neonatal stool finding requires immediate pediatric GI referral?
Acholic or clay-colored stools
267What urine finding is a red flag for neonatal cholestasis?
Dark tea-colored urine
268What should be suspected in an ill-appearing jaundiced infant?
Bacterial sepsis, HSV, or metabolic decompensation
269What metabolic disease may cause severe neonatal jaundice?
Galactosemia
270Should breast milk jaundice be diagnosed before excluding conjugated hyperbilirubinemia?
No
271In what form should fat-soluble vitamins be supplemented during severe cholestasis?
Water-soluble or solubilized form
272What are the six PFIC-related genes listed in the lecture?
ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, and MYO5B
273What does IBAT stand for?
Ileal bile acid transporter
274Which drugs are IBAT inhibitors?
Odevixibat and maralixibat
275What is the therapeutic role of odevixibat and maralixibat?
Reduce cholestatic pruritus and serum bile acids
276Which conditions may be treated with IBAT inhibitors?
PFIC and Alagille syndrome
277What potential surgical benefit do IBAT inhibitors provide?
Reduced need for biliary diversion in selected patients
278What causes breastfeeding jaundice?
Insufficient fluid intake during the first week of life
279What complications may occur in breastfeeding jaundice?
Dehydration and hypernatremia
280When does breastfeeding jaundice commonly occur?
During the first week of life
281What is breast milk jaundice?
Persistent indirect hyperbilirubinemia in thriving, healthy, well-fed infants
282What type of bilirubin is elevated in breast milk jaundice?
Unconjugated bilirubin
283What substances in breast milk contribute to breast milk jaundice?
Inhibitors of glucuronyl transferase
284How does breast milk affect bilirubin absorption?
Enhances intestinal bilirubin absorption
285When does breast milk jaundice typically become evident?
Later than breastfeeding jaundice
286When does breast milk jaundice generally decline?
During the second to third week of life
287What should be considered in severe or persistent neonatal jaundice?
Other medical causes
288What temporary feeding change may be considered for persistently high bilirubin?
Formula for 24–48 hours
289Does phototherapy require cessation of breastfeeding?
No
290When should breastfeeding resume after temporary formula feeding?
After serum bilirubin declines
291What should parents do with breast milk during temporary formula feeding?
Continue expressing and collecting breast milk
292What are the main differences between breastfeeding jaundice and breast milk jaundice?
Breastfeeding jaundice is due to inadequate intake; breast milk jaundice causes prolonged indirect hyperbilirubinemia
293What is the most important bilirubin fraction to check in prolonged neonatal jaundice?
Direct/conjugated bilirubin
294What is the gold-standard invasive investigation for suspected biliary atresia listed in the lecture?
Intraoperative cholangiogram